trending Market Intelligence /marketintelligence/en/news-insights/trending/_ixdhmzwqq2fe2bmbcc_ew2 content esgSubNav
In This List

ReWalk Robotics gets another Nasdaq noncompliance notice

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ReWalk Robotics gets another Nasdaq noncompliance notice

ReWalk Robotics Ltd. said it received a second letter of deficiency from Nasdaq for failure to comply with certain requirements.

According to the notice, as of March 31, the company failed to reach the minimum $2.5 million shareholders' equity requirement, and the alternative $35 million market value of listed securities and $500,000 net income requirements.

The letter is a notice of deficiency, not delisting, and will have no effect on the company's listing on the Nasdaq Capital Market at the moment.

In December 2017 the company submitted a compliance plan to address the first deficiency letter, and showed compliance for the minimum shareholders' equity requirement. However, Nasdaq decided to issue a second noncompliance notice since the company had a shareholders' deficiency as of March 31. The company could only show compliance as of that date based only on a balance sheet reflecting the pro forma effect of the issuance of 4 million ordinary shares in a private placement.

Israel-based ReWalk has until July 2 to achieve compliance with the alternative $35 million market value of listed securities or submit a plan to regain compliance with any of the alternative shareholders' equity, or net income requirements.

ReWalk Robotics is a medical device company which designs and sells exoskeletons for wheelchair-bound individuals.